In the newly created position, Huguet will report directly into Rick Wagner, Ph.D, X-Chem's CEO. Huguet and Clark will be members of X-Chem's executive committee.
Huguet is a senior pharmaceutical research and development leader with over 20 years of industry experience. Most recently, Huguet was head of internal research at Alexion, focusing on rare and devastating diseases.
Prior to this, she spent 18 years at Pfizer running programs from the early phases of drug discovery to the early clinical development of programs through PhIIb. Huguet's most recent position at Pfizer was chief scientific officer, inflammation and remodeling unit.
Clark is a pioneer in the field of DNA encoded libraries of small molecules and is a founding scientist at X-Chem. He has overseen the development of the X-Chem DEX platform, including the creation of 200 bn molecules in X-Chem's screening library, along with the successful application of the platform that has led to 44 licensed programs to X-Chem's 22 active partnerships.
Privately owned X-Chem's mission is to apply its powerful product engine to the discovery of small molecule leads against high-value therapeutic targets. X-Chem has established partnerships with pharmaceutical companies, biotechnology organizations, and academic centers.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP